DARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the provided data, Dare Bioscience Inc (DARE) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive financial performance, clear upward technical trends, or strong trading signals. While there is a potential catalyst from FDA clearance for a Phase 2 clinical trial, the company's poor financials and lack of significant trading sentiment suggest holding off on this investment for now.
The MACD is slightly positive at 0.0076, indicating mild bullish momentum, but the RSI is neutral at 43.386. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below the pivot level of 1.686, suggesting a downward trend. Overall, the technical indicators do not support a strong buy signal.
FDA clearance for the DARE-HPV treatment study, allowing the initiation of a Phase 2 clinical trial for high-risk HPV infection.
The stock also shows no significant trading trends from hedge funds or insiders.
In Q3 2025, revenue dropped to 2262 (-94.57% YoY), net income fell to -3562766 (-24.24% YoY), and EPS dropped to -0.28 (-49.09% YoY). Gross margin remained stable at 100%. Overall, the financials indicate poor performance with no signs of growth.
No data available for analyst ratings or price target changes.
